CoronaryAtlas logo
CoronaryAtlas
Glucose-Dependent Insulinotropic Polypeptide
Pathway / Off-pathway / systemic markers

Glucose-Dependent Insulinotropic Polypeptide

GIPpeptide

GIP dysregulation associates with metabolic dysfunction and accelerated coronary atherosclerosis in Type 1 MI.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleMetabolic/endocrine hormone; role in coronary calcification reflects systemic metabolic and risk factors.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
0
C — non-Type-I
67
A — assay feasibility
66
E — evidence strength
52
T1DI (composite)
6
Specificity differential (R−C)-66.7
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressn/a
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedn/a
Coverage: 2/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 14 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)
Collection tube
K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Competitive/sandwich immunoassay or LC-MS/MS
Reagent / substrate
Anti-peptide antibody; or isotope-labeled internal standard (MS)
Platform
Immunoassay / LC-MS/MS
Turnaround · availability
Send-out / research · Research-grade

Literature evidence(1)